Citation:Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schröder FH, et al 2014

From Cancer Guidelines Wiki

Citation


Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schröder FH, et al. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol 2014 Feb;65(2):329-36 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23954085.


This is a publication of ERSPC

Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schröder FH, et al 2014For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?Tracy Tsangcompleted
Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schröder FH, et al 2014 2For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?Suzanne Hughescompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. Discussion
  2. PSA Testing strategies
Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Citation:Bokhorst_LP,_Bangma_CH,_van_Leenders_GJ,_Lous_JJ,_Moss_SM,_Schröder_FH,_et_al_2014&oldid=87247"